ArticleThe Journal of infectious diseases2019

The Ability of a Cytomegalovirus ELISPOT Assay to Predict Outcome of Low-Level CMV Reactivation in Hematopoietic Cell Transplant Recipients.

Lynn El Haddad et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.